CVS
FY2026 Q1 · Calendar Q2 2026
CVS Health Corp.
CVS Health delivered a decisive Q1 2026 beat, with adjusted EPS of $2.57 topping consensus by nearly 18% on revenue of $100.4 billion, a 6% year-over-year increase. The company raised full-year 2026 EPS guidance from $7.00-$7.20 to $7.30-$7.50, reflecting growing confidence in Aetna's margin recovery, pharmacy biosimilar conversions, and new AI-driven initiatives. Management struck a confident tone across all segments, earning a bullish score of 82. The stock rallied 7.6% on the report and has drifted an additional 9% higher since, with volume at 2.1x baseline. The quarter marks a clear inflection from the prior quarter's maintained guidance, driven by stronger-than-expected Medicare Advantage performance and accelerating operational leverage.
EPS surprise+17.9%
Market move+7.6%
